Publication:
Pharmacological effects of chatuphalatika in hyperuricemia of gout

dc.contributor.authorVilasinee Hirunpanich Satoen_US
dc.contributor.authorBunleu Sungthongen_US
dc.contributor.authorPrasob Orn Rinthongen_US
dc.contributor.authorNarawat Nuamnaichatien_US
dc.contributor.authorSupachoke Mangmoolen_US
dc.contributor.authorSavita Chewchidaen_US
dc.contributor.authorHitoshi Satoen_US
dc.contributor.otherShowa Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMahasarakham Universityen_US
dc.date.accessioned2019-08-23T10:40:21Z
dc.date.available2019-08-23T10:40:21Z
dc.date.issued2018-01-01en_US
dc.description.abstract© 2018 The Author(s). Context: Chatuphalatika (CTPT), is a Thai herbal formulation mixture of Phyllanthus emblica Linn. (Euphorbiaceae), Terminalia belerica Linn. (Combretaceae), T. chebula and the fruit of T. arjuna (Roxb.) Wight & Arn. CTPT is considered to exert anti-inflammatory and antihyperuricemic effects, but there have been no reports to demonstrate these pharmacological effects in a quantitative manner. Objectives: To investigate the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT. Materials and methods: Antioxidant activities of CTPT extracts were measured in vitro by DPPH, ABTS and FRAP assays, and anti-inflammatory effect by measuring inflammatory mediator production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages. The mechanism of the hypouricemic effect was investigated using oxonate-induced hyperuricemic ddY mice treated with oral administrations of CTPT at 250, 500 and 1000 mg/kg. Results: Antioxidant activities of CTPT measured by ABTS and FRAP assays were 1.35 g TEAC/g extract and 10.3mmol/100 g extract, respectively. IC50 for the inhibition of DPPH radical was 13.8 µg/mL. CTPT (10 µg/mL) significantly downregulated the mRNA expression of TNF-α and iNOS in RAW 264.7 cells. Lineweaver-Burk analysis of the enzyme kinetics showed that CTPT inhibited xanthine oxidase (XOD) activity in a noncompetitive manner with the Ki of 576.9 µg/mL. Oral administration of CTPT (1000 mg/kg) significantly suppressed uric acid production by inhibiting hepatic XOD activity, and decreased plasma uric acid levels in hyperuricemic mice by approximately 40% (p<0.05). Conclusions: This study demonstrated for the first time the antioxidative, anti-inflammatory and antihyperuricemic effects of CTPT in vivo and in vitro, suggesting a possibility of using CTPT for the treatment of hyperuricemia in gout.en_US
dc.identifier.citationPharmaceutical Biology. Vol.56, No.1 (2018), 76-85en_US
dc.identifier.doi10.1080/13880209.2017.1421235en_US
dc.identifier.issn17445116en_US
dc.identifier.issn13880209en_US
dc.identifier.other2-s2.0-85046831580en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/45310
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046831580&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePharmacological effects of chatuphalatika in hyperuricemia of gouten_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046831580&origin=inwarden_US

Files

Collections